14063

524212

WANBURY

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

WANBURY LIMITED Share Price Today

WANBURY LIMITED is currently trading at ₹268.5, up by ₹1.14 from the previous close. The stock touched an intraday high of ₹272.00 and a low of ₹261.40 during the latest trading session. Over the past one year, WANBURY LIMITED has delivered a loss of 8.66%, while the stock has gained 10.21% in the last one month.

WANBURY LIMITED performance

Today’s low Today’s high
₹ 261.40 ₹ 272.00
₹ 265.95
52 week low 52 week high
₹ 161.50 ₹ 320.95
₹ 265.95
Open Price ₹ 270.05
Prev. Close ₹ 267.35
Volume (Shares) 34129.00
Total traded value ₹ 90.76
Upper Circuit ₹ 320.80
Lower Circuit ₹ 213.90
info

Investment Returns

Over 1 Month 10.21% Over 3 Months 6.68% Over 6 Months 15.69% Over 1 Year -8.66%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

WANBURY LIMITED fundamentals


  • Market cap (Cr) 929.70
  • P/E Ratio (TTM) 14.11
  • Beta 1.32
  • Book Value / share 41.34
  • Return on equity 18.30%
  • EPS (TTM) 19.95
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 21.70
info icon alternate text
  • Market cap (Cr) 933.10
  • P/E Ratio (TTM) 14.11
  • Beta 1.12
  • Book Value / share 41.34
  • Return on equity 18.30%
  • EPS (TTM) 19.95
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 21.70
info icon alternate text

WANBURY LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 164.58
Operating Expense 146.02
Net Profit 21.70
Net Profit Margin (%) 13.18
Earnings Per Share (EPS) 7.26
EBITDA 26.46
Effective Tax Rate (%) -43.11
Particulars DEC 2025 (Values in Cr)
Revenue 162.45
Operating Expense 146.76
Net Profit 15.76
Net Profit Margin (%) 9.70
Earnings Per Share (EPS) 4.52
EBITDA 26.86
Effective Tax Rate (%) 0.69
Particulars SEP 2025 (Values in Cr)
Revenue 160.06
Operating Expense 145.10
Net Profit 15.18
Net Profit Margin (%) 9.48
Earnings Per Share (EPS) 4.58
EBITDA 25.98
Effective Tax Rate (%) -0.13
Particulars JUN 2025 (Values in Cr)
Revenue 163.18
Operating Expense 149.92
Net Profit 13.49
Net Profit Margin (%) 8.26
Earnings Per Share (EPS) 4.12
EBITDA 24.79
Effective Tax Rate (%) 0.88
Particulars MAR 2025 (Values in Cr)
Revenue 172.00
Operating Expense 154.79
Net Profit 20.26
Net Profit Margin (%) 11.77
Earnings Per Share (EPS) 6.18
EBITDA 31.46
Effective Tax Rate (%) -6.29
Particulars MAR 2026 (Values in Cr)
Revenue 650.27
Operating Expense 587.80
Net Profit 66.13
Net Profit Margin (%) 10.16
Earnings Per Share (EPS) 20.42
EBITDA 104.09
Effective Tax Rate (%) -10.58
Particulars MAR 2025 (Values in Cr)
Revenue 599.51
Operating Expense 573.46
Net Profit 30.53
Net Profit Margin (%) 5.09
Earnings Per Share (EPS) 9.32
EBITDA 79.81
Effective Tax Rate (%) -3.31
Particulars MAR 2024 (Values in Cr)
Revenue 575.65
Operating Expense 547.85
Net Profit 30.40
Net Profit Margin (%) 5.28
Earnings Per Share (EPS) 9.29
EBITDA 72.99
Effective Tax Rate (%) 1.23
Particulars MAR 2023 (Values in Cr)
Revenue 499.65
Operating Expense 510.25
Net Profit -10.40
Net Profit Margin (%) -2.08
Earnings Per Share (EPS) -3.18
EBITDA 23.48
Effective Tax Rate (%) -1.06
Particulars MAR 2022 (Values in Cr)
Revenue 511.19
Operating Expense 507.93
Net Profit 81.47
Net Profit Margin (%) 15.93
Earnings Per Share (EPS) 25.29
EBITDA 113.19
Effective Tax Rate (%) -0.43
Particulars MAR 2025 (Values in Cr)
Book Value / Share 16.26
ROE % 19.98
ROCE % 21.03
Total Debt to Total Equity 3.38
EBITDA Margin 13.90
Particulars MAR 2024 (Values in Cr)
Book Value / Share 6.70
ROE % 49.77
ROCE % 33.25
Total Debt to Total Equity 0.00
EBITDA Margin 13.10
Particulars MAR 2023 (Values in Cr)
Book Value / Share -10.07
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 5.43
Particulars MAR 2022 (Values in Cr)
Book Value / Share -7.27
ROE % 306.03
ROCE % 16.14
Total Debt to Total Equity 0.00
EBITDA Margin 7.33
Particulars MAR 2021 (Values in Cr)
Book Value / Share -62.46
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 5.20
Particulars MAR 2025 (Values in Cr)
Book Value / Share 16.26
ROE % 18.30
ROCE % 19.97
Total Debt to Total Equity 3.38
EBITDA Margin 13.31
Particulars MAR 2024 (Values in Cr)
Book Value / Share 6.70
ROE % 38.26
ROCE % 31.94
Total Debt to Total Equity 8.94
EBITDA Margin 12.63
Particulars MAR 2023 (Values in Cr)
Book Value / Share -2.26
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 4.70
Particulars MAR 2022 (Values in Cr)
Book Value / Share 0.57
ROE % 37.03
ROCE % 17.45
Total Debt to Total Equity 0.00
EBITDA Margin 7.26
Particulars MAR 2021 (Values in Cr)
Book Value / Share -52.23
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 5.20
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 12.82
Total Assets 413.91
Total Liabilities 413.91
Total Equity 59.27
Share Outstanding 3
Price to Book Ratio 14.43
Return on Assets (%) 7.37
Return on Capital (%) 13.13
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.89
Total Assets 343.11
Total Liabilities 343.11
Total Equity 27.94
Share Outstanding 3
Price to Book Ratio 21.77
Return on Assets (%) 16.30
Return on Capital (%) 40.78
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.93
Total Assets 303.52
Total Liabilities 303.52
Total Equity -32.81
Share Outstanding 3
Price to Book Ratio -16.51
Return on Assets (%) -3.42
Return on Capital (%) -33.19
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 25.31
Total Assets 352.54
Total Liabilities 352.54
Total Equity -23.41
Share Outstanding 3
Price to Book Ratio 149.12
Return on Assets (%) 23.10
Return on Capital (%) 186.85
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 11.70
Total Assets 289.17
Total Liabilities 289.17
Total Equity -156.24
Share Outstanding 2
Price to Book Ratio -1.59
Return on Assets (%) -4.35
Return on Capital (%) -301.65
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 12.82
Total Assets 413.91
Total Liabilities 413.91
Total Equity 59.27
Share Outstanding 3
Price to Book Ratio 14.43
Return on Assets (%) 7.37
Return on Capital (%) 13.13
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.89
Total Assets 343.11
Total Liabilities 343.11
Total Equity 27.94
Share Outstanding 3
Price to Book Ratio 21.77
Return on Assets (%) 8.85
Return on Capital (%) 22.15
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.89
Total Assets 301.89
Total Liabilities 301.89
Total Equity -7.25
Share Outstanding 3
Price to Book Ratio -16.51
Return on Assets (%) -3.44
Return on Capital (%) -18.28
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 25.27
Total Assets 351.00
Total Liabilities 351.00
Total Equity 2.18
Share Outstanding 3
Price to Book Ratio 149.12
Return on Assets (%) 23.21
Return on Capital (%) 117.72
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 11.66
Total Assets 287.60
Total Liabilities 287.60
Total Equity -130.65
Share Outstanding 2
Price to Book Ratio -1.59
Return on Assets (%) -4.38
Return on Capital (%) -42.35
Particulars MAR 2025 (Values in Cr)
Net Income 29.55
Cash from Operations 26.47
Cash from Investing -51.17
Cash from Financing 25.73
Net change in Cash 0.66
Free Cash Flow 75.49
Particulars MAR 2024 (Values in Cr)
Net Income 56.33
Cash from Operations 4.88
Cash from Investing -16.62
Cash from Financing 13.87
Net change in Cash 1.94
Free Cash Flow 22.30
Particulars MAR 2023 (Values in Cr)
Net Income -10.28
Cash from Operations 19.97
Cash from Investing -8.83
Cash from Financing -31.99
Net change in Cash -21.03
Free Cash Flow 32.59
Particulars MAR 2022 (Values in Cr)
Net Income 81.12
Cash from Operations 40.68
Cash from Investing 0.58
Cash from Financing -28.58
Net change in Cash 12.52
Free Cash Flow 50.34
Particulars MAR 2021 (Values in Cr)
Net Income -12.40
Cash from Operations 17.81
Cash from Investing 8.04
Cash from Financing -17.38
Net change in Cash 7.34
Free Cash Flow 22.24
Particulars MAR 2025 (Values in Cr)
Net Income 29.55
Cash from Operations 26.47
Cash from Investing -51.17
Cash from Financing 25.73
Net change in Cash 0.66
Free Cash Flow 75.49
Particulars MAR 2024 (Values in Cr)
Net Income 30.78
Cash from Operations 4.88
Cash from Investing -16.62
Cash from Financing 13.87
Net change in Cash 1.94
Free Cash Flow 22.30
Particulars MAR 2023 (Values in Cr)
Net Income -10.28
Cash from Operations 19.97
Cash from Investing -8.83
Cash from Financing -31.99
Net change in Cash -21.03
Free Cash Flow 32.59
Particulars MAR 2022 (Values in Cr)
Net Income 81.12
Cash from Operations 40.68
Cash from Investing 0.58
Cash from Financing -28.58
Net change in Cash 12.52
Free Cash Flow 50.34
Particulars MAR 2021 (Values in Cr)
Net Income -12.40
Cash from Operations 17.81
Cash from Investing 8.04
Cash from Financing -17.38
Net change in Cash 7.34
Free Cash Flow 22.24
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 13.39 1.56 248.29 23.12 38.85
BLISS GVS PHARMA LTD. 438.10 35.56 3.89 4646.32 118.35 462.70
CIPLA LTD. 1388.80 29.47 3.25 112193.56 1165.55 1672.20
FERMENTA BIOTECH LTD. 338.80 14.94 2.45 997.12 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 22.66 4.17 248.29 23.12 38.85
AMRUTAJAN HEALTH LTD 557.75 25.00 4.35 1612.49 490.00 789.95
ASTRAZENECA PHARMA IND LT 8243.90 107.66 23.61 20609.75 7630.00 10653.05
BLISS GVS PHARMA LTD. 438.10 47.26 4.02 4646.32 118.35 462.70

WANBURY LIMITED shareholding pattern

Holding
56.39%
43.01%
0.58%
86.69%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

WANBURY LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
266.10 -0.46 redarrow
red-green-graph indicator
2 Bearish
14 Bullish
  • 5 Days 265.50
  • 26 Days 264.90
  • 10 Days 265.50
  • 50 Days 260.60
  • 12 Days 265.80
  • 100 Days 254.60
  • 20 Days 265.70
  • 200 Days 250.70
258.07 PIVOT
First Support 251.88 First Resistance 262.13 Second Support 247.82 Second Resistance 268.32 Third Support 241.63 Third Resistance 272.38
RSI 54.67 ADX 24.79 MACD 0.73 Williams % R -61.13 Commodity Channel Index (CCI) 11.27
Date 2026-06-12 Week 61636.00 Same Day 93943.00 Month 82806.00
1 Year 1.33 3 Year 1.16
Over 1 Month
10.21% down
Over 1 Year
-8.66% down
Over 3 Months
6.68% down
Over 3 Years
70.13% down
Over 6 Months
15.69% down
Over 5 Years
21.93% down

WANBURY LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
29 Jul 2010 1.0 Final 02 Aug 2010 Equity shares
12 Mar 2009 0.5 Final 16 Mar 2009 Equity shares
13 Sep 2007 2.0 Final 17 Sep 2007 Equity shares
20 Feb 2006 0.0 Interim 01 Jan 0001 Equity shares
28 Jul 2005 0.0 Final 01 Aug 2005 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
29 Jul 2010 1.0 Final 02 Aug 2010 Equity shares
12 Mar 2009 0.5 Final 16 Mar 2009 Equity shares
13 Sep 2007 2.0 Final 17 Sep 2007 Equity shares
20 Feb 2006 0.0 Interim 01 Jan 0001 Equity shares
28 Jul 2005 0.0 Final 01 Aug 2005 Equity shares

Top Gainers

Top Losers

Wanbury share result highlights

The Wanbury share price has experienced fluctuations following the company’s recent financial results. Wanbury reported moderate revenue growth, driven by strong demand in the pharmaceutical sector. However, profit margins were impacted by rising input costs and operational expenses. The company’s focus on expanding its product portfolio and enhancing its manufacturing capabilities contributed positively to overall revenue. Despite these efforts, net profit remained under pressure, reflecting the challenges faced in maintaining profitability. Nevertheless, Wanbury’s strategic initiatives in research and development have positioned it for future growth, keeping the Wanbury share price stable, with cautious optimism from investors about the company’s long-term performance.

Wanbury share annual reports

Wanbury’s annual reports provide a comprehensive overview of the company’s financial performance, which directly impacts the Wanbury share price. The reports highlight key metrics such as revenue growth, operational efficiency, and cost management. They also outline the company’s strategic initiatives, including investments in research and development, which are essential for future growth. Investors use these reports to assess Wanbury’s financial stability and long-term potential. The annual reports are crucial for understanding the company’s progress and the factors that drive the Wanbury share price, offering valuable insights into its operational and financial outlook.

Wanbury share dividend

Wanbury has not been a regular dividend-paying company in recent years due to its focus on reinvesting profits into business expansion and research initiatives. The company’s primary goal has been to strengthen its financial position and improve operational efficiencies. As a result, dividend payments have been limited, which may not attract income-focused investors. However, as Wanbury continues to stabilise its financial performance, future dividend payouts may become a possibility. This strategic reinvestment has helped support the long-term stability of the Wanbury share price.

Popular FAQs

Who is the CEO of Wanbury?

As of the latest available information, the CEO of Wanbury is Mr. Arvind Doshi. He is responsible for overseeing the company’s strategic direction and overall operations, which directly impact the Wanbury share price. His focus on expanding Wanbury’s product offerings and strengthening its position in the pharmaceutical sector plays a key role in driving the company’s financial performance and long-term growth.

 

When was Wanbury established?

Wanbury was established in 1990. Since its inception, the company has grown to become a prominent player in the pharmaceutical industry, specialising in active pharmaceutical ingredients and formulations. Over the years, Wanbury has expanded its operations, contributing to its strong market presence. This long-standing history has had a positive impact on the Wanbury share price, reflecting the company’s stability and growth potential.

 

What factors influence the Wanbury share price?

Several factors influence the Wanbury share price, including the company’s financial performance, revenue growth, and profitability margins. External factors such as regulatory changes, demand for pharmaceutical products, and market competition also play a significant role. Additionally, investor sentiment regarding Wanbury’s ability to manage costs, expand its product portfolio, and maintain profitability affects the share price movement.

 

Is Wanbury debt free?

Wanbury is not entirely debt-free, but it maintains a manageable level of debt. The company’s focus on effective debt management ensures that its financial obligations do not negatively impact its profitability. This controlled debt structure contributes to the overall stability of the Wanbury share price, as investors generally prefer companies with a balanced approach to managing liabilities and sustaining long-term growth.

 

How has the Wanbury share price performed over the past year?

Over the past year, the Wanbury share price has experienced moderate fluctuations, reflecting the company’s financial performance and market conditions. While the company has seen revenue growth, challenges related to rising input costs and operational expenses have impacted profitability. Despite these hurdles, the Wanbury share price has remained relatively stable, with investors maintaining cautious optimism about the company’s future growth potential.

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Wanbury Ltd?

Answer Field

Wanbury Ltd share price is for NSE ₹ 268.50 & for BSE ₹ 268.40 as on Jun 16 2026 03:30 PM.

What is the Market Cap of Wanbury Ltd Share?

Answer Field

The market cap of Wanbury Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 16 2026 03:30 PM.

What is the 52 Week High and Low of Wanbury Ltd?

Answer Field

The 52 Week High and Low of Wanbury Ltd for NSE is ₹ 320.95 and ₹ 161.50 and for BSE is ₹ 329.00 and ₹ 162.00.

What is 1 year return for Wanbury Ltd?

Answer Field

The 1 year returns on the stock has been -14.48%.

What is the P/E Ratio of Wanbury Ltd Share?

Answer Field

As on Jun 16 2026 03:30 PM the price-to-earnings (PE) ratio for Wanbury Ltd share is 14.11.

What is the PB ratio of Wanbury Ltd Share?

Answer Field

As on Jun 16 2026 03:30 PM, the price-to-book (PB) ratio for Wanbury Ltd share is 41.34.

How to Buy Wanbury Ltd Share?

Answer Field

You can trade in Wanbury Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Wanbury Ltd Share on Bajaj Broking App?

Answer Field

To buy Wanbury Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Wanbury Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Wanbury?

Answer Field

As of the latest available information, the CEO of Wanbury is Mr. Arvind Doshi. He is responsible for overseeing the company’s strategic direction and overall operations, which directly impact the Wanbury share price. His focus on expanding Wanbury’s product offerings and strengthening its position in the pharmaceutical sector plays a key role in driving the company’s financial performance and long-term growth.

When was Wanbury established?

Answer Field

Wanbury was established in 1990. Since its inception, the company has grown to become a prominent player in the pharmaceutical industry, specialising in active pharmaceutical ingredients and formulations. Over the years, Wanbury has expanded its operations, contributing to its strong market presence. This long-standing history has had a positive impact on the Wanbury share price, reflecting the company’s stability and growth potential.

What factors influence the Wanbury share price?

Answer Field

Several factors influence the Wanbury share price, including the company’s financial performance, revenue growth, and profitability margins. External factors such as regulatory changes, demand for pharmaceutical products, and market competition also play a significant role. Additionally, investor sentiment regarding Wanbury’s ability to manage costs, expand its product portfolio, and maintain profitability affects the share price movement.

Is Wanbury debt free?

Answer Field

Wanbury is not entirely debt-free, but it maintains a manageable level of debt. The company’s focus on effective debt management ensures that its financial obligations do not negatively impact its profitability. This controlled debt structure contributes to the overall stability of the Wanbury share price, as investors generally prefer companies with a balanced approach to managing liabilities and sustaining long-term growth.

How has the Wanbury share price performed over the past year?

Answer Field

Over the past year, the Wanbury share price has experienced moderate fluctuations, reflecting the company’s financial performance and market conditions. While the company has seen revenue growth, challenges related to rising input costs and operational expenses have impacted profitability. Despite these hurdles, the Wanbury share price has remained relatively stable, with investors maintaining cautious optimism about the company’s future growth potential.

No results found

close-image
Get Free Demat Account*
+91
close-img
Authorise with OTP
Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|